Nevertheless, sub-analysis of the results of the phase II trial and another study indicated that codrituzumab showed prognostic merit for HCC patients with a high immunogenicity related to ADCC and a high expression of GPC3 [65,66]. Here, GPC3 is linked to hepatocellular carcinoma.